BioCentury
ARTICLE | Finance

Unfinished business

Why more crossover rounds in January do not herald a return to 2015 levels

February 1, 2016 8:00 AM UTC

An uptick in crossover-backed private rounds was about the only bright spot in January, but even that may just be the fading glow of days gone by.

Last month saw six crossover rounds for private biotechs - one more than in all of 4Q15. In the first nine months of last year, some of the most active crossover funds were putting money to work in up to eight private biotech companies per quarter (see BioCentury, Nov. 2, 2015). ...